NEUE SULFENAMIDE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG IN ARZNEIMITTELN UND DEREN HERSTELLUNG

5-Phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease

Heterocyclic and phenyl compounds.

A compound of formula (i)r-s(o)nch2ch2ch=cf2, or a salt thereof, wherein n is 0, 1 or 2; and r is a group of formulae (ii)to (xxi), wherein: the s ch2ch2ch=cf2 group is at least one of r1 (when attached to a carbon atom). R2, r3, r4, r5 or r6; r1 (when attached to a ca atom)r2, r3 r4, r5 and r6 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, alkoxy, alkenyloxy, alkynyloxy, hydroxyalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted heteroaryloxyalky, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, haloalkenyloxy, haloalkynyloxy, halogen, hydroxy, cyano, notro, -nr7r8, -nr7cor8, -nr7csr8, -nr7so2r8 ...

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.

Heterocyclic and phenyl compounds

5-Phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease

5-Phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease

(4,4-Difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity

Heterocyclic and phenyl compounds

NEW PHENYLALANINDERIVAT

SUBSTITUTED 4-ARYLBUTYRSÄUREDERIVATE AS MATRIX METALLOPROTEASE INHIBITORS

(4,4-DIFLUORBUT-3-ENYLTHIO) - HETEROCYCKI OR CARBOCYCLI RING SUBSTITUTED CONNECTIONS WITH PESTICIDER EFFECT

SUBSTITUTED BENZOYLKETONE, PROCEDURES FOR YOUR PRODUCTION AND YOUR USE AS HERBICIDES

Subsitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors

LISOFYLLINE ANALOGS AND METHODS FOR USE

The present invention provides analogs of formula (I) of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF. The compounds (II) are used to treat diabetes, inflammatory and autoimmune conditions. wherein R1 is hydrogen or a group having the formula -C(=O)R3, wherein R is lower alkyl, and R2 is selected from the group consisting of.

SUBSTITUTED BENZOYL KETONES AND THEIR USE AS HERBICIDES

ПРОИЗВОДНЫЕ 5-ФЕНИЛПЕНТАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНОЙ МЕТАЛЛОПРОТЕИНАЗЫ ДЛЯ ЛЕЧЕНИЯ АСТМЫ И ДРУГИХ ЗАБОЛЕВАНИЙ

Настоящее изобретение относится к соединениям структурной формулы I, где n имеет значение от 1 до 5; R1 представляет собой необязательно замещенный алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, алкокси, арилокси, алкенилокси или алкинилокси; R2 представляет собой алкенил, алкинил, арил, гетероциклил, гетероарил, циклоалкил, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5Rx, -NHC(=О)OR4, -NHSO2R4, C(=Y)NR4R5, C(=О)OR6 [где Y представляет собой атом кислорода или серы], OR5, -OC(=О)NR4R5, О-ацил, S(О)mR4, -SO2N(R4)2, циано, амидино или гуанидино [где R4 представляет собой алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, гетероарилалкил, гетероциклилалкил или циклоалкилалкил и m имеет значение 0-2; R5 представляет собой водород или R4; Rx представляет собой R4 или -SO2N(R4)2 и R6 представляет собой водород, алкил, циклоалкил, аралкил, гетероарилалкил, гетероциклилалкил или циклоалкилалкил]; R3 представляет собой водород, фтор, алкил, циклоалкилалкил ...

ПРОИЗВОДНЫЕ 5-ФЕНИЛПЕНТАНОЕВОЙ КИСЛОТЫ КАК ИНГИБИТОРЫ МАТРИЧНОЙ МЕТАЛЛОПРОТЕИНАЗЫ ДЛЯ ЛЕЧЕНИЯ АСТМЫ И ДРУГИХ ЗАБОЛЕВАНИЙ

Данное изобретение касается соединений структурной Формулы I: где n равно целому числу от 1 до 5; R1 представляет собой необязательно замещенный алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, алкокси, арилокси, алкенилокси или алкинилокси; R2 представляет собой алкенил, алкинил, арил, гетероциклил, гетероарил, циклоалкил, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5Rx, -NHC(=O)OR4, -NHSO2R4, C(=Y)NR4R5, C(=O)OR6 [де Y представляет собой кислород или серу], OR5, -O(C=O)NR4R5,О-ацил, S(O)mR4, -SO2N(R4)2, циано, амидино или гуанидино [где R4 представляет собой алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, гетероарилалкил, гетероциклил алкил или циклоалкилалкил и m равно целому числу от 0 до 2; R5 представляет собой водород или R4; Rx представляет собой R4 или -SO2N(R4)2 и R6 представляет собой водород, алкил, циклоалкил, аралкил, герероарилалкил, гетероциклилалкил или циклоалкилалкил]; R3 представляет собой водород, фтор, алкил, циклоалкилалкил ...

ПРОИЗВОДНЫЕ 5-ФЕНИЛПЕНТАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНОЙ МЕТАЛЛОПРОТЕИНАЗЫ ДЛЯ ЛЕЧЕНИЯ АСТМЫ И ДРУГИХ ЗАБОЛЕВАНИЙ

Настоящее изобретение относится к соединениям структурной формулы (I), где n имеет значение от 1 до 5; R1 представляет собой необязательно замещенный алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, алкокси, арилокси, алкенилокси или алкинилокси; R2 представляет собой алкенил, алкинил, арил, гетероциклил, гетероарил, циклоалкил, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5Rx, -NHC(=O)OR4, -NHSO2R4, C(=Y)NR4R5, C(=O)OR6 (где Y представляет собой атом кислорода или серы), OR5, -OC(=O)NR4R5, О-ацил, S(O)mR4, -SO2N(R4)2, циано, амидино или гуанидино (где R4 представляет собой алкил, алкенил, алкинил, циклоалкил, арил, гетероциклил, гетероарил, аралкил, гетероарилалкил, гетероциклилалкил или циклоалкилалкил и m имеет значение 0-2; R5 представляет собой водород или R4; Rx представляет собой R4 или -SO2N(R4)2 и R6 представляет собой водород, алкил, циклоалкил, аралкил, гетероарилалкил, гетероциклилалкил или циклоалкилалкил); R3 представляет собой водород, фтор, алкил, циклоалкилалкил ...

SUBSTITUTED BENZOYL KETONES, METHODS FOR PRODUCING THEM AND THEIR USE AS HERBICIDES

Cette invention concerne des cétones de benzoyle substituées de formule (I), dans laquelle: n vaut 0, 1, 2, ou 3; A est une liaison simple ou alcandiyle (alkylène); R1¿ est hydrogène, ou alkyle ou cycloalkyle éventuellement substitué; R2¿ est hydrogène, cyano, carbamoyle, halogène, ou alkyle, alkoxy, alkoxycarbonyle, alkylthio, alkylsulfinyle ou alkylsulfonyle éventuellement substitué; R3¿ est hydrogène, nitro, cyano, carboxy, carbamoyle, thiocarbamoyle, halogène, ou alkyle, alkoxy, alkylthio, alkylsulfinyle, alkylsulfonyle, alkylamino, dialkylamino ou dialkylaminosulfonyle éventuellement substitué; R4¿ est nitro, cyano, carboxy, carbamoyle, thiocarbamoyle, halogène, ou alkyle, alkoxy, alkylthio, alkylsulfinyle, alkylsulfonyle, alkylamino, dialkylamino ou dialkylaminosulfonyle éventuellement substitué; et Z est un groupe hétérocyclique, monocyclique ou bicyclique, saturé ou non, possédant 4 à 12 éléments, comprenant 1 à 4 hétéroatomes (jusqu'à 4 atomes d'azote et éventuellement - de manière ...

NOVEL PHENYLALANINE DERIVATIVE

The following phenylalanine derivative having an α4 integrin inhibitory effect, its analogs and remedies for various diseases in which α4 integrin participates.

Fungicides

Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators

Primarily, the present invention relates to compounds of the formula (I) defined below and to their use as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The present invention also relates to herbicidal or plant growth-regulating compositions comprising one or more compounds of the formula (I). Moreover, the present invention relates to processes for preparing the compounds of the formula (I).

HETEROCYCLIC PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) Z1 and Z2 are each independently selected from the group consisting of N, O, and C with the proviso that at least one of Z1 and Z2 is N; (f) Z3 is selected from the group consisting of N, O, and C. (g) R8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C4 alkylenyl and halo; (h) R9 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl, halo, aryl- C0-C4 alkyl, heteroaryl, C1-C6 allyl, and OR29.

MOULD FIGHT MEANS.

SULPHENAMIDES DERIVATIVES

3-METHOXY-2-(SUBSTITUTED PHENYL)-PROPENOIC ACID ESTERS AS FUNGICIDES

5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES

The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5, -NHC(=Y)R4, - NHC(=Y)NR5R.chi., -NHC(=O)OR4, -NHSO2R4, C(=Y)NR4R5, C(=O)OR6 [wherein Y is oxygen or sulphur], OR5, -O(C=O)NR4R5, O-acyl, S(O)mR4, -SO2N(R4)2, cyano, amidino or guanidino [wherein R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R5 is hydrogen or R4; Rx is R4 or -SO2N(R4)2 and R6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR4, -OC(=O)NR4R5, O-acyl, NH2, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5Rx, -NHC(=O)OR4, -NHSO2R4, and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES

The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R 2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5,-NHC(=Y)R4,-NHC(=Y)NR 5Rg,-NHC(=O)OR4,-NHSO2R 4, C(=Y)NR4R5, C(=O)OR6 [wherein Y is oxygen or sulphur], OR5,-O(C=O)NR4R5, O-acyl, S(O)mR4,-SO2N(R4) 2, cyano, amidino or guanidino [wherein R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R5 is hydrogen or R4; Rx is R 4 or-SO2N(R4)2 and R6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR4,-OC(=O)NR4R5, O-acyl, NH2, NR4 R5,-NHC(=Y)R4,-NHC(=Y)NR5Rx,-NHC(=O)OR4,-NHSO2R4, and ...

derivados de ácido 5-fenil-pentanóico, seus processos de preparação, composição farmacêutica compreendendo os mesmos e processo de separação dos referidos derivados

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

Schimmelbekämpfungsmittel.

MOULD FIGHT MEANS.

INHIBITION OF MATRIXMETALLOPROTEASEN BY 2 - SUBSTITUIERTE-4 (4-SUBSTITUIERTPHENYL) - 4 - OXOBUTANSÄUREN

LISOFYLLIN ANALOGIKA AND YOUR PHARMACEUTICAL USES

5-PHENYL-PENTANSÄUREDERIVATE AS MATRIXMETALLOPROTEINASE INHIBITORS FOR the TREATMENT OF ASTHMA AND OTHER ILLNESSES

Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids

RUTHENIUM-CATALYZED CYCLOADDITION OF ALKYNES AND ORGANIC AZIDES

A convenient process for the regioselective synthesis of 1 ,5-disubstituted 1 ,2,3-triazoles and 1 ,4,5-trisubstituted 1 ,2,3-triazoles from organic azides and alkynes employs catalytic ruthenium.

SUBSTITUTED 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containi ng them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have generalized formula (I) wherein R1 represents C6-C12 alkyl; C5-C12 alkoxy; C5-C12 alkylthio; a polyether of formula R2O(C2H4O)a- in which a is 1 or 2 and R2 is C1-C5 alkyl , phenyl, or benzyl; and substituted alkynyl of formula R3(CH2)b-CC-; in which b is 1-10 and R3 is H-, HO-, or R4O- in which R4 is C1-C3 alkyl, phenyl, or benzyl. The alkyl, phenyl, and benzyl portions of R1 may bear at least one pharmaceutically-acceptable substituent. The subscript n is 2-4. R5 represen ts phenyl; imidoyl of 4-12 carbon atoms; (3H)-benzo-1,2,3-triazin-4-on-3-yl; N- saccharinyl; (2H)-phthalazin-1-on-2-yl; 2-benzoxazolin-2-on-3-yl; 5,5- dimethyloxazolidine-2,4-dion-3-yl; and thiazolidine-2,4-dion-3-yl; with the phenyl and benzo portions of R5 permissibly bearing at least one pharmaceutically-acceptable substituent ...

ACID DERIVATIVES 4-ARILBUTIRICO REPLACED LIKE INHIBISOR OF METALOPROTEASA MATRIX

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS IHIBIDORES DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y UN PROCESO PARA USAR LOS MISMOS A FIN DE TRATAR UNA DIVERSIDAD DE TRASTORNOS FISIOLOGICOS, LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERALIZA I, ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS MATERIALES.

INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS

ЗАМЕЩЕННЫЕ БЕНЗОИЛКЕТОНЫ И ГЕРБИЦИДНОЕ СРЕДСТВО НА ИХ ОСНОВЕ

FIELD: organic chemistry, herbicides, agriculture. SUBSTANCE: invention relates to new substituted benzoylketones of the general formula (I): , all possible tautomeric forms and possible salts that can represent active substance as a component of herbicide agent. In the formula (I) A means (C 1 -C 4 )-alkyl; R 1 means cyclo-(C 3 -C 6 )-alkyl; R 2 means hydrogen atom (H), cyano-group (CN); R 3 means hydrogen atom (H), halogen atom, CF 3 , (C 1 -C 4 )-alkylsulfonyl; R 4 means halogen atom; X means groups: or wherein R 5 means (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy-group, (C 1 -C 4 )-alkylthio-group, di-(C 1 -C 6 -alkyl)-amino-group; R 6 means (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy-group, cyclo-(C 3 -C 6 )-alkyl; n = 0 or 1 including all possible tautomeric forms and possible salts. Compounds of the formula (I) elicit herbicide activity and can be used in herbicide composition. EFFECT: valuable properties of compounds. 3 cl, 1 sch, 3 tbl, 13 ex ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (51) ÌÏÊ 7 (11) (13) 2 245 330 C2 C 07 D 233/32, 249/12, A 01 N 43/50, 43/653 ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (21), (22) Çà âêà: 2001133347/04, 26.04.2000 (24) Äàòà íà÷àëà äåéñòâè ïàòåíòà: 26.04.2000 (30) Ïðèîðèòåò: 08.05.1999 DE 19921424.7 (45) Îïóáëèêîâàíî: 27.01.2005 Áþë. ¹ 3 (73) Ïàòåíòîîáëàäàòåëü(ëè): ÁÀÉÅÐ ÀÊÖÈÅÍÃÅÇÅËÜØÀÔÒ (DE) (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 10.12.2001 (86) Çà âêà PCT: EP 00/03712 (26.04.2000) (54) ÇÀÌÅÙÅÍÍÛÅ ÁÅÍÇÎÈËÊÅÒÎÍÛ È ÃÅÐÁÈÖÈÄÍÎÅ ÑÐÅÄÑÒÂÎ ÍÀ ÈÕ ÎÑÍÎÂÅ (57) Ðåôåðàò: Èçîáðåòåíèå îòíîñèòñ ê íîâûì çàìåùåííûì áåíçîèëêåòîíàì îáùåé ôîðìóëû (I) , R U 2 2 4 5 3 3 0 Àäðåñ äë ïåðåïèñêè: 103064, Ìîñêâà, óë. Êàçàêîâà, 16, ÍÈÈÐ-Êàíöåë ðè , "Ïàòåíòíûå ïîâåðåííûå Êâàøíèí, Ñàïåëüíèêîâ è Ïàðòíåðû", Êâàøíèíó Â.Ï. C 2 C 2 (87) Ïóáëèêàöè PCT: WO 00/68204 (16.11.2000) ãäå R 5 îçíà÷àåò Ñ1-Ñ4àëêèë, Ñ1-Ñ4àëêîêñè, ãäå âñåì âîçìîæíûì òàóòîìåðíûì ôîðìàì è âîçìîæíûì ñîë ì, êîòîðûå ìîãóò ïðåäñòàâë ...

ЗАМЕЩЕННЫЕ БЕНЗОИЛЦИКЛОГЕКСАНДИОНЫ, ГЕРБИЦИДНОЕ СРЕДСТВО НА ИХ ОСНОВЕ, ИСХОДНОЕ СОЕДИНЕНИЕ

FIELD: organic chemistry, herbicides, agriculture. SUBSTANCE: invention describes substituted benzoylcyclohexanediones of the general formula (I): wherein m = 0 or 1; n = 0 or 1; A means a single bond or alkanediyl (alkylene) with 1-4 carbon atoms; R 1 means hydrogen atom or unsubstituted alkyl with from 1 to 6 carbon atoms; R 2 means methyl; R 3 means hydrogen atom, nitro-, cyano-group, halogen atom, alkyl with from 1 to 4 carbon atoms substituted with halogen atom, alkoxy-group with from 1 to 4 carbon atoms or alkyl sulfonyl with from 1 to 4 carbon atoms; R 4 means nitro-group, halogen atom, unsubstituted alkyl with from 1 to 4 carbon atoms of that substituted with halogen atom; Z means heterocycle, and herbicide agent based on thereof. Also, invention describes substituted derivatives of benzoic acid of the general formula (III): wherein values n, A, R 3 , R 4 and Z are given above. These compounds represent the parent substances used for preparing compound of the formula (I). Compounds of the formula (I) elicit high and selective herbicide activity. EFFECT: valuable properties of compounds. 7 cl, 8 tbl, 7 ex

(4,4-difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity

Ruthenium-catalyzed cycloaddition of alkynes and organic azides

A convenient process for the regioselective synthesis of 1 ,5-disubstituted 1 ,2,3-triazoles and 1 ,4,5-trisubstituted 1 ,2,3-triazoles from organic azides and alkynes employs catalytic ruthenium.

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases

The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NRR, -NHC(=Y)R, - NHC(=Y)NRR, -NHC(=O)OR, -NHSOR, C(=Y)NRR, C(=O)OR [wherein Y is oxygen or sulphur], OR, -O(C=O)NRR, O-acyl, S(O)R, -SON(R), cyano, amidino or guanidino [wherein R is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R is hydrogen or R; R is R or -SON(R) and R is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR, -OC(=O)NRR, O-acyl, NH, NRR, -NHC(=Y)R, -NHC(=Y)NRR, - NHC(=O)OR, -NHSOR, and to processes for the synthesis of the ...

NOVEL PHENYLALANINE DERIVATIVE

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE

Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and or modulate intracellular triacylglycerol and cholesterol stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and or increase insulin sensitivity ; and or modulate insulin secretion from pancreatic beta cells. More particularly said disorders are selected from the group consisting of insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperclycemia, dislipidemia, obesity, abnormalities of ...

SUBSTITUTED BENZOYL KETONES, METHODS FOR PRODUCING THEM AND THEIR USE AS HERBICIDES

The invention relates to novel substituted benzoyl ketones of formula (I), wherein n represents 0, 1, 2 or 3; A represents a simple bond or alkanediyl (alkylene); R1 represents hydrogen or optionally substituted alkyl or cycloalkyl; R2 represents hydrogen, cyano, carbamoyl, halogen, or optionally substituted alkyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl or alkylsulfonyl; R3 represents hydrogen, nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; R4 represents nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; and Z represents an optionally substituted 4 to 12- membered, saturated or unsaturated, monocyclic or bicyclic, heterocyclic grouping containing 1 to 4 hetero atoms (up to 4 nitrogen atoms and optionally, - alternatively or additionally - an oxygen atom or a sulphur atom, or an SO2 grouping), which also contains one to three oxo-groups (C=O) and/or thioxo-groups (C=S) as constituents of the heterocycle. The invention also relates to methods for producing the inventive substituted benzoyl ketones and to their use as herbicides.

(4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY

A compound of formula (I), or a salt thereof, whenein n is 0, 1 or 2; and R is a group of formulae (II) to (XXI), wherein: the S(O)nCH2CH2CH=CF2 group is at least one of R1 (when attached to a carbon atom), R2, R3, R4, R5 or R6; R1 (when attached to a carbon atom), R2, R3, R4, R5 and R6 are each independentiy hydrogen, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, alkoxy, alkenyloxy, alkynyloxy, hydroxyalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionaily substituted arylalkoxy, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted heteroaryloxyalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, haloalkenyloxy, haloalkynyloxy, halogen, hydroxy, cyano, nitro, -NR7R8, -NR7COR8, -NR7CSR8, -NR7SO2R8, -N(SO2R7)(SO2R8), -COR7, -CONR7R8, -alkylCONR7R8, CR7NR8, -COOR7, -OCOR7, -SR7, -SOR7, SO2R7, -alkylSR7, -alkylSOR7, -alkylSO2R7, -OSO2R7, -SO2NR7R8, -CSNR7R8, SiR7R8R9, -OCH2CO2R7, -OCH2CH2CO2R7, -CONR7SO2R8, -alkylCONR7SO2R8, -NHCONR7R8, -NHCSNR7R8, or an adjacent pair of R1, R2 R3, R4, R5 and R6 when taken together form a fused 5- or 6-membered carbocyclic or heterocyclic ring; R1 (when attached to a nitrogen atom) is hydrogen, optionally substituted alkyl, cycloalkyl, alkylcycloalkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryl, optionally substituted heteroarylakyl, optionally substituted heteroaryloxyalkyl, haloalkyl, hydroxy, cyano, nitro, -NR7R8, -NR7COR8, NR7CSR8, -NR7COOR8, -NR7SO2R8, -N(SO2R7)(SO2R8), -COR7, -CONR7R8, -alkylCONR7R8, -CR7NR8, -COOR7, -OCOR7, -SOR7 -SO2R7 -alkylSR7 -alkylSOR7 -alkylSO2R7, -OSO2R7, SO2NR7NR8, -SR7, -SOR7, -SO2R7, -CSNR7R8, -SiR7R8R7, ...

INHIBITION OF MATRIX METALLOPROTEASES BY 2-SUBSTITUTED-4-(4-SUBSTITUTEDPHENYL)-4-OXOBUTYRIC ACIDS

Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have generalized formula (1) wherein r is 0-2, T is selected from (a) and (b) and R40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis of degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

(4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY

Dans un composé de formule (I) ou dans un de ses sels, n vaut 0, 1 ou 2; et R représente un groupe de formule (II) à (XXI), où le groupe S(O)nCH2CH2CH=CF2 correspond au moins à une des références R1 (lorsqu'il est lié à un atome de carbone), R2, R3, R4, R5 ou R6 lesquels représentent chacun indépendamment hydrogène, ou bien alkyle, ou alcényle éventuellement substitué, alkynyle, cycloalkyle, alkylcycloalkyle, alcoxy, alkényloxy, alkynyloxy, hydroxyalkyle, alcoxyalkyle, ou bien aryle, arylalkyle, hétéroaryle, hétéroarylalkyle, aryloxy, arylalcoxy, aryloxyalkyle, hétéroaryloxy, hétéroarylalcoxy ou hétéroaryloxyalkyle éventuellement substitué, ou bien haloalkyle, haloalkényle, haloalkynyle, haloalcoxy, haloalkényloxy, haloalkynyloxy, halogène, hydroxy, cyano, nitro, -NR7R8, -NR7COR8, -NR7CSR8, -NR7SO2R8, -N(SO2R7)(SO2R8), -COR7, -CONR7R8, -alkylCONR7R8, CR7NR8, -COOR7, -OCOR7, -SR7, -SOR7, SO2R7, -alkylSR7, -alkylSOR7, -alkylSO2R7, -OSO2R7, -SO2NR7R8, -CSNR7R8, SiR7R8R9, -OCH2CO2R7, -OCH2CH2CO2R7 ...

1,2,3-Triazine fungicides

Fungicidal compounds have the formula (I): <IMAGE> in which X and Y are independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, C2-4 alkynyloxy, phenyl, benzyl, benzyloxy, cyano, isocyano, thiocyanato, isothiocyanato, nitro, NR<1>R<2>, NR<1>OR<2>, N3, NHCOR<1>, NR<1>CO2R<2>, NHCONR<1>R<2>, N=CHNR<1>R<2>, NHSO2R<1>, OR<1>, OCOR<1>, OSO2R<1>, SR<1>, SOR<1>, SO2R<1>, SO2OR<1>, SO2NR<1>R<2>, COR<1>, CR<1>=NOR<2>, CHR<1>CO2R<2>, CO2R<1>, CONR<1>R<2>, CSNR<1>R<2>, CH3O2C.C=CH.OCH3, 1-(imidazol-1-yl)vinyl, a 5-membered heterocyclic ring containing one, two or three nitrogen heteroatoms, or a 5-or 6-membered heterocyclic ring containing one or two oxygen or sulphur heteroatoms, optionally a nitrogen heteroatom and optionally one or two oxo or thioxo substituents; or X and Y, when ortho to one another, join to form a 5- or 6-membered aliphatic or aromatic ring optionally containing one or two oxygen, sulphur or nitrogen atoms or one, two or three nitrogen atoms; A, B, D, G, U and V are independently hydrogen, halogen, C1-4 alkyl C1-4 alkoxy, cyano, nitro or trifluoromethyl; and R<1> and R<2> are independently hydrogen, C1-4 alkyl or phenyl; the aliphatic moieties of any of the foregoing being optionally substituted with one or more of, halogen, cyano, OR<1>,

(4,4-difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity

Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids

Production method for epoxy compound

The present invention addresses the problem of providing a method for producing an epoxy compound having an epoxy ring bonded to a triazinetrione ring via a long-chained alkylene group, wherein an epoxy compound having an epoxidated olefin moiety is efficiently obtained at good yield by using an olefin compound of a specific structure. A method for producing an epoxy compound represented by formula (2) (in formula (2), R1 through R9 are each independently a hydrogen atom or a methyl group, and n1 through n3 are each independently an integer of 1 to 4), including causing an alkaline substance, a nitrile compound, hydrogen peroxide, or a triolefin compound represented by formula (1) (in formula (1), R1 through R9 are each independently a hydrogen atom or a methyl group, n1 through n3 are each independently an integer of 1 to 4) to react in a solvent.

ПРОИЗВОДНЫЕ 4,4-ДИФТОРБУТ-3-ЕНА И СПОСОБ ИХ ПОЛУЧЕНИЯ, СОДЕРЖАЩИЕ ИХ СЕЛЬСКОХОЗЯЙСТВЕННЫЕ КОМПОЗИЦИИ И ИСПОЛЬЗОВАНИЕ ИХ В КАЧЕСТВЕ ИНСЕКТИЦИДОВ, АКАРИЦИДОВ ИЛИ НЕМАТОЦИДОВ

FIELD: organic chemistry, chemical technology, agriculture. SUBSTANCE: invention describes the novel compounds of the general formula (I): R-S(O) n CH 2 CH 2 CH=CF 2 or its salt where values n, R are given in p. 1 of the invention claim. Compounds show insecticide, acaricide or nematocide activity. Invention describes also method of their synthesis and agriculture compositions based on compounds of the formula (I). EFFECT: improved method of synthesis, enhanced effectiveness of composition. 14 cl, 3 tbl, 33 ex

HETEROCYCLIC INTERMEDIATES

Subsituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors

Inhibition of matrix metalloproteases by 2-substituted-4- (4-substitutedphenyl)-4-oxobutyric acids

Substituted benzoyl ketones, methods for producing them and their use as herbicides

RUTHENIUM-CATALYZED CYCLOADDITION OF ALKYNES AND ORGANIC AZIDES

A convenient process for the regioselective synthesis of 1 ,5-disubstituted 1 ,2,3-triazoles and 1 ,4,5-trisubstituted 1 ,2,3-triazoles from organic azides and alkynes employs catalytic ruthenium.

FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I), wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases

MATRIX METALLOPROTEINASE INHIBITORS

The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.

HEMMUNG VON MATRIXMETALLOPROTEASEN DURCH 2-SUBSTITUIERTE-4-(4-SUBSTITUIERTPHENYL)-4-OXOBUTANSÄUREN

Compounds for use in the treatment of liver disease

COMPOUNDS AND USE THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE

INHIBITION DES MATRICES METALLOPROTEASES PAR LA SUBSTITUTION D'ACIDE BIARYL OXOBUTYRIQUE

LA MATRICE METALLOPROTEASE INHIBITANT LES COMPOSES, LES COMPOSITIONS PHARMACEUTIQUES ET LA METHODE DE TRAITEMENT DE LA MALADIE EN UTILISANT CES COMPOSES SONT PRESENTES. LES COMPOSES DE CETTE INVENTION ONT LES FORMULES GENERALISEES : R40 is A MONO-OU BI-HETEROCYCLIC STRUCTURE. CES COMPOSES SONT UTILES POUR INHIBITANT LES MATRICES METALLOPROTEASES ET COMBATTANT LES CONDITIONS OU MMP’S : (a) ALLEGER LES EFFETS D’OSTEOARTHRITIS. RHEUMATOID ULCERATION DE LA CORNEE, PROTEINURIA. MALADIE ANEURYSMAL AORTIQUE. EPIDERMLYSIS DISTROPHOBIQUE. BULLOSA DES CONDITIONS MENANT A DES REACTIONS INFLAMMATOIRES OSTEOPENIAS EN MEDIATION PAR L’ACTIVITE MMP. MALADIE TEMPERO MANDIBULAIRE DES JOINTS DES MALADIES DEMYELANTE DU SYSTEME NERVEUX : (b) RETARDER LA TUMEUR METASTASIS ET LA PERTE DEGENERATIVE DU CARTILAGE SUIVANT UNE BLESSURE TRAUMATIQUE DES JOINTS : (C) REDUIT LA THROMBOSIS CORONAIRE DE LA RUPTURE DE LA PLAQUE ATHROSCLEROTIQUE ; OU (e) EFFET DU CONTROLE DE LA NAISSANCE. CETTE PRESENTE INVENTION DONNE AUSSI ...

A PYRAZOLE DERIVATIVE AS PPAR MODULATOR

The present invention is directed to a compound, {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid and pharmaceutical uses thereof.

LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES

The present invention provides analogs of formula (I) of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF. The compounds (II) are used to treat diabetes, inflammatory and autoimmune conditions. wherein R1 is hydrogen or a group having the formula -C(=O)R3, wherein R is lower alkyl, and R2 is selected from the group consisting of.

Lisofylline analogs and methods for use

The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.

Fungicides

Compounds

The present invention relates to compounds of formula (1): where R1 and R2 are independently hydrogen or optionally substituted C1-C6 alkyl groups and R1 and R2 may be fused to form a heterocycle; and/or Het is an optionally substituted heterocyclic group joined through nitrogen provided Het is not and their potential use, for example in the treatment of a1-antitrypsin deficiency (AATD).

Substituted benzoyl ketones, methods for producing them and their use as herbicides

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases

SUBSTITUTED 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have generalized formula (I) wherein R1 represents C6-C12 alkyl; C5-C12 alkoxy; C5-C12 alkylthio; a polyether of formula R2O(C2H4O)a- in which a is 1 or 2 and R2 is C1-C5 alkyl, phenyl, or benzyl; and substituted alkynyl of formula R3(CH2)b-CC-; in which b is 1-10 and R3 is H-, HO-, or R4O- in which R4 is C1-C3 alkyl, phenyl, or benzyl. The alkyl, phenyl, and benzyl portions of R1 may bear at least one pharmaceutically-acceptable substituent. The subscript n is 2-4. R5 represents phenyl; imidoyl of 4-12 carbon atoms; (3H)-benzo-1,2,3-triazin-4-on-3-yl; Nsaccharinyl; (2H)-phthalazin-1-on-2-yl; 2-benzoxazolin-2-on-3-yl; 5,5dimethyloxazolidine-2,4-dion-3-yl; and thiazolidine-2,4-dion-3-yl; with the phenyl and benzo portions of R5 permissibly bearing at least one pharmaceutically-acceptable substituent ...

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Substituierte Benzoylketone

The invention relates to novel substituted benzoyl ketones of formula (I), wherein n represents 0, 1, 2 or 3; A represents a simple bond or alkanediyl (alkylene); R<1> represents hydrogen or optionally substituted alkyl or cycloalkyl; R<2> represents hydrogen, cyano, carbamoyl, halogen, or optionally substituted alkyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl or alkylsulfonyl; R<3> represents hydrogen, nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; R<4> represents nitro, cyano, carboxy, carbamoyl, thiocarbamoyl, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; and Z represents an optionally substituted 4 to 12-membered, saturated or unsaturated, monocyclic or bicyclic, heterocyclic grouping containing 1 to 4 hetero atoms (up to 4 nitrogen atoms and optionally ...

Fused 1,2,3-triazin-4-one 2-N-oxides and process for their preparation

The novel hetarene-fused or benzo-fused 1,2,3-triazin-4-one 2-N-oxides can be prepared by reacting o-aminonitriles of aromatic nitrogen heterocycles or substituted benzenes with nitrating agents in acidic medium at a temperature from -20 to +100 DEG C. Suitable nitrating agents are, for example, nitric acid, inorganic nitrates, alkyl nitrates, acetyl nitrate, benzoyl nitrate and N2O5. The acids employed as the acid medium are, for example, sulphuric acid, alkylsulphonic acids, arylsulphonic acids, hydrofluoric acid and trifluoroacetic acid or mixtures thereof.

FUNGICIDES

A compound having the general formula (XIII): wherein X, Y and Z, which are the same or different, are hydrogen or a standard substituent; W is a C-linked optionally substituted six membered heterocyclic ring other than pyrimidinyl, containing two to four nitrogen atoms, and wherein adjacent substituents may together form a fused aromatic or hetero-aromatic ring and A is oxygen or sulphur. No specific examples are disclosed. These compounds are intermediates for fungicides claimed in GB 8717427.2 (GB 2 195 119 A).

FUNGICIDAL PROPENOIC ACID DERIVATIVES

Fungicidal propenoic acid derivatives

Fungicidal compounds of the formula (I) : and stereoisomers thereof, wherein R<1> is optionally substituted aryl or optionally substituted heteroaryl; Y is oxygen, sulphur or NR<4>; R<2>, R<3> and R<4>, which may be the same or different, are hydrogen, C1-4 alkyl or C2-4 alkenyl; X is halogen, C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, nitro or cyano; and n is 0 or an integer of 1 to 4; provided that when Y is oxygen, n is 0 and R<1> is unsubstituted phenyl at least one of R<2> and R<3> is other than hydrogen or methyl.

MATRIX METALLOPROTEINASE INHIBITORS

Organic electroluminescence device

To provide: an organic compound which functions as a material for a highly efficient and highly durable organic EL element, exhibits excellent hole injection and hole transport performance, has electronic stopping power, and exhibits the excellent properties of being highly stable as a thin film and having high light emission efficiency; and an organic EL element which uses this compound and exhibits high durability and high efficiency. An organic EL element provided with a first hole transport layer, a second hole transport layer, a green light-emitting layer, and an electron transport layer which are positioned between a positive electrode and a negative electrode in this order from the positive electrode side, the organic EL element being characterized in that an arylamine compound represented by general formula (1) is contained in one or more layers among the layered films positioned between the electron transport layer and the first hole transport layer or the second transport layer ...

Derived of 5-fenile pentanoico acid like inhibitors of the metalloproteinasi of the matrix for the treatment of asthma and other diseases

5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES

The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5, -NHC(=Y)R4, - NHC(=Y)NR5Rχ, -NHC(=O)OR4, -NHSO2R4, C(=Y)NR4R5, C(=O)OR6 [wherein Y is oxygen or sulphur], OR5, -O(C=O)NR4R5, O-acyl, S(O)mR4, -SO2N(R4)2, cyano, amidino or guanidino [wherein R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R5 is hydrogen or R4; Rx is R4 or -SO2N(R4)2 and R6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR4, -OC(=O)NR4R5, O-acyl, NH2, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5Rx, - NHC(=O)OR4, -NHSO2R4, and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

Pure 2-heterocyclylmethyl-benzoic acid derivative preparation in high yield, for use as pharmaceutical or agrochemical intermediate, from phthalide compound and nitrogen-containing heterocycle

Preparation of 2-((N-bonded heterocyclyl)-methyl)-benzoic acid derivatives (I) involves reacting a phthalide (II) with a nitrogen-containing heterocycle (III) (or its metal salt) in presence of a polar aprotic diluent and a optionally a basic reaction auxiliary. Preparation of 2-heterocyclylmethyl-benzoic acid derivatives of formula (I) involves reacting a phthalide of formula (II) with a nitrogen-containing heterocycle of formula H-Y (III) (or its metal salt) in presence of a polar aprotic diluent and a optionally a basic reaction auxiliary. n = 0-3; X = NO2, CN, CONH2, CSNH2, halo or (all optionally substituted) alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino or dialkylaminosulfonyl; Y = N-bonded heterocyclyl.

A PYRAZOLE DERIVATIVE AS PPAR MODULATOR

Matrix metalloproteinase inhibitors

The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.

Fused heterocyclic compounds as sodium channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and 5 diabetes. In particular embodiments, the structure of the compounds is given by Formula (I), wherein Q, R , X , X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

INHIBITION OF MATRIX METALLOPROTEASES BY 2-SUBSTITUTED-4-(4-SUBSTITUTEDPHENYL)-4-OXOBUTYRIC ACIDS

Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have generalized formula (1) wherein r is 0-2, T is selected from (a) and (b) and R40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis of degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods ...

ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, sol-vates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

MATRIX METALLOPROTEINASE INHIBITORS

The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.

FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS

Use of compounds for decreasing activity of hormone-sensitive

Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

Lisofylline analogs and methods for use

The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.

Organic compound and organic light-emitting element

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device. In the formula [1], R 1 to R 18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

Substituted 5-hydroxy-2-heteroaryl-3-phenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators

Primarily, the present invention relates to compounds of the formula (I) defined below and to their use as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The present invention also relates to herbicidal or plant growth-regulating compositions comprising one or more compounds of the formula (I). Moreover, the present invention relates to processes for preparing the compounds of the formula (I). 2. The compound of formula (I) and/or salt thereof according to claim 1 , whereinQ represents a mono- or bicyclic heteroaromatic radical having in total 2 to 9 carbon ring atoms, where the heteroaromatic radical Q contains 1, 2, 3 or 4 heteroatoms in the heteroaromatic ring and the heteroatom or the heteroatoms are selected from the group consisting of N, O, and S.3. The compound of formula (I) and/or salt thereof as claimed in claim 1 , whereinQ represents a mono- or bicyclic heteroaromatic radical selected from the group consisting of pyrimidinyl, pyridinyl, pyridazinyl, pyrazinyl, thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazinyl, quinolyl, isoquinolyl, cinnolinyl-, quinazolinyl, quinoxalinyl, pteridinyl, indolyl and phthalazinyl.5. The compound of formula (I) and/or salt thereof as claimed in claim 1 , wherein{'sup': '1', 'Rrepresents hydrogen or a hydrolyzable radical having in total up to 30 carbon atoms, with preference a hydrolyzable radical having in total 1 to 24 carbon atoms, optionally having in total 1 to 20 carbon atoms.'}6. The compound of formula (I) and/or salt thereof as claimed in claim 1 , wherein{'sup': 1', '1, 'claim-text': represents an optionally substituted hydrocarbon radical or an optionally substituted heterocyclyl radical, or', {'sup': b', 'a', 'b', 'c', 'a', 'b, 'Rrepresents a radical of the formula SiRRR, or —NRR,'}, {'sup': a', 'b', 'c', 'a', 'b, 'where each of the radicals Rand ...

Organic electroluminescence device

[Object] It is an object of the present invention to provide an organic compound having excellent properties such as excellent hole injection/transport performance, electron blocking performance, high stability in a thin-film state, and high light emission efficiency as a material for a highly efficient organic EL device having a high durability, and a highly efficient organic EL device having a high durability by using this compound. [Solving Means] An organic EL device, including, between an anode and a cathode, at least a first hole transport layer, a second hole transport layer, a green light-emitting layer, and an electron transport layer in the stated order from a side of the anode, the organic EL device being characterized in that, the second hole transport layer, or at least one of stacked films disposed between the first hole transport layer and the electron transport layer contains an arylamine compound represented by the following general formula (1). (In the formula, Ar 1 , Ar 2 , Ar 3 , and Ar 4 may be the same as or different from each other, and each represent a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted fused polycyclic aromatic group. L 1 represents a divalent group of a substituted or unsubstituted aromatic hydrocarbon, a divalent group of a substituted or unsubstituted aromatic heterocyclic, or a divalent group of a substituted or unsubstituted fused polycyclic aromatic. R 1 , R 2 , and R 3 each represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a cyano group, a nitro group, a linear or branched alkyl group having 1 to 6 carbon atoms which may have a substituted group, a cycloalkyl group having 5 to 10 carbon atoms which may have a substituted group, a linear or branched alkenyl group having 2 to 6 carbon atoms which may have a substituted group, a linear or branched alkyloxy group having 1 to 6 carbon atoms which ...

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fungicides

내용 없음. No content.

Method for producing epoxy compound

本发明的课题是提供环氧环介由长链亚烷基而与三嗪三酮环结合了的环氧化合物的制造方法，其中，通过使用特定结构的烯烃化合物，有效率地收率高地获得烯烃部分环氧化了的环氧化合物。式(2)：(式(2)中，R 1 ～R 9 各自独立地为氢原子或甲基，n1～n3各自独立地为1～4的整数。)所示的环氧化合物的制造方法，其包括下述步骤：使下述式(1)：(式(1)中，R 1 ～R 9 各自独立地为氢原子或甲基，n1～n3各自独立地为1～4的整数。)所示的三烯烃化合物、过氧化氢、腈化合物和碱性物质在溶剂中进行反应。

Substituted benzoylcyclohexandiones

본 발명은 하기 일반식 (I)의 신규 치환된 벤조일사이클로헥산디온, 그의 제조방법 및 제초제로서의 그의 용도에 관한 것이다: The present invention relates to novel substituted benzoylcyclohexanediones of the general formula (I), their preparation and their use as herbicides: 상기 식에서, Where m, n, A, R 1 , R 2 , R 3 , R 4 및 Z 는 각각 명세서에 정의된 바와 같다. m, n, A, R 1 , R 2 , R 3 , R 4 and Z are each as defined in the specification.

A kind of synthetic method of U-triazine analog

本发明公开一种连三嗪类似物的合成方法，所述连三嗪类似物的结构式如下： ，其中，所述R 1 为烷基、烯基、芳基或氢；所述R 2 为烷基、烯基、芳基、呋喃基、吡啶基、吡咯基或氢；所述R 3 为‑CN、‑NO 2 或‑COR 5 ，所述R 5 为烷基、烷氧基或芳基；所述R 4 为‑CN、‑NO 2 或‑COR 6 ，所述R 6 为烷基、烷氧基或芳基；将 与

Method for producing epoxy compound

Fluorine-containing compound

Provided is a fluorine-containing compound from which high water repellency is obtained even with less fluorine atoms. This compound is represented by general formula (1): L-(R 1 -X-Rf-Y-R 2 ) n (in the formula, L represents a n-valent organic group, n represents an integer of 1 or more, Rf represents a linear or branched fluoroalkylene group optionally having an ether bond and including 1-4 of at least any of a CF 2 unit, a CFH unit, and a CFRf' unit (Rf' represents a fluoroalkyl group having one carbon atom), R 1 represents a direct bond or a linear or branched hydrocarbon group having 1-4 carbon atoms, R 2 represents a linear or branched hydrocarbon group having 7-29 carbon atoms, not including fluorine atoms, and optionally having an ether bond, and X and Y each independently represent a direct bond or a divalent linkage group).

Mixtures comprising triazine compounds and at least one electrolyte solvent are useful as a solvent additive for electrochemical cells, preferably lithium batteries and supercapacitors

Mixtures comprising triazine compounds and at least one electrolyte solvent are claimed. Mixtures comprising triazine compounds of formula (I) - (III) and at least one electrolyte solvent are claimed. R<1>-R<3> = H, F or optionally substituted 1-6C alkyl or 4-6C cycloalkyl Independent claims are included for: (i) an electrolyte comprising a triazine compound of formula (I) - (III), an electrolyte solvent or mixture and a conductive salt, preferably LiPF6; (ii) adducts comprising a triazine compound of formula (I)-(III) and dimethyl carbonate.

FUNGICIDES AND PROCEDURES FOR PREPARING IT

Antifungal.

Fungicides.

Fungicidal compounds of the formula (I) : <CHEM> and stereoisomers thereof, wherein R<1> is optionally substituted aryl or optionally substituted heteroaryl; Y is oxygen, sulphur or NR<4>; R<2>, R<3> and R<4>, which may be the same or different, are hydrogen, C1-4 alkyl or C2-4 alkenyl; X is halogen, C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, nitro or cyano; and n is 0 or an integer of 1 to 4; provided that when Y is oxygen, n is 0 and R<1> is unsubstituted phenyl at least one of R<2> and R<3> is other than hydrogen or methyl.

Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors

Substd. benzoyl ketones, methods for producing them and their use as herbicides

本发明涉及新的结构式(I)的取代的苯甲酰基酮，其中：n代表0，1，2或3，A代表单键或代表烷二基(亚烷基)，R 1 代表氢或代表任选取代的烷基或环烷基，R 2 代表氢、氰基、氨基甲酰基、卤素或代表任选取代的烷基、烷氧基、烷氧基羰基、烷硫基、烷基亚磺酰基或烷基磺酰基，R 3 代表氢、硝基、氰基、羧基、氨基甲酰基、硫代氨基甲酰基、卤素或代表任选取代的烷基、烷氧基、烷硫基、烷基亚磺酰基、烷基磺酰基、烷基氨基、二烷基氨基或二烷基氨基磺酰基，R 4 代表硝基、氰基、羧基、氨基甲酰基、硫代氨基甲酰基、卤素，或代表任选取代的烷基、烷氧基、烷硫基、烷基亚磺酰基、烷基磺酰基、烷基氨基、二烷基氨基或二烷基氨基磺酰基，以及Z代表任选取代的4-至12-元，饱和或不饱和的，单环或二环的杂环基，该杂环含有1-4个杂原子(至多4个氮原子并任选-替换或加入-1个氧原子或1个硫原子，或1个SO 2 基团)以及该杂环还含有1-3个氧代基(C＝O)和/或硫代基(C＝S)作为杂环的一部分。本发明还涉及制备本发明取代苯甲酰基酮的方法和作为除草剂的用途。

Fused heterocyclic compounds as sodium channel modulators

Fungicides

يتعلق هذا الإختراع بمشتقات لحمض البروبينويك مفيدة كمضادات للفطريات ، وبطرق تحضيرها، وبمستحضرات مضادة للفطريات تحتوي عليها ، وبطرق لإستخدامها لمكافحة الفطريات ، وبخاصة الإصابات الفطرية بالنباتات .

4-ARILBUTIRATE ACID-SUBSTITUTED ACID DRUGS AS METALLOPROTEASE MATRIX INHIBITORS

Method for producing 2-heterocyclyl methyl benzoic acid derivatives

The invention relates to a novel method for the production of 2-heterocyclyl methyl benzoic acid derivatives of general formula (I), wherein n, X and Z have the meaning cited in the description, providing good yields and high purity. The invention is characterized in that phthalide of general formula (II), wherein n and X have the meaning cited in the description, is reacted with nitrogen heterocycles of general formula (III): H-Z, wherein Z has the meaning cited in the description, or with nitrogen heterocycle metal salts of general formula (II) in the presence of an aprotic polar diluent and optionally in the presence of a basic auxiliary reaction agent.

Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors

NEW PHENYL ALANIDE DERIVATIVE

Hetero-aryl compounds having herbicidal, fungicidal and insecticidal activity

Fungicidal compounds of the formula (I): and stereoisomers thereof, wherein R 1 is optionally substituted aryl or optionally substituted heteroaryl; Y is oxygen, sulphur or NR 4 ; R 2 , R 3 and R 4 , which may be the same or different, are hydrogen, C 1-4 alkyl or C 2-4 alkenyl; X is halogen, C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, nitro or cyano, and n is 0 or an integer of 1 to 4; provided that when Y is oxygen, n is 0 and R 1 is unsubstituted phenyl at least one of R 2 and R 3 is other than hydrogen or methyl.

Lysophylline analogs and methods of use

The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.

Phenylthioether compound and use thereof

本发明公开了一种苯基硫醚类化合物，结构如通式I所示：

DERIVATIVES OF 3-ARILBUTIRIC ACID REPLACED AS INHIBITORS OF THE METALOPROTEASE OF MATRIX AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compuestos con actividad inhibitoria de la metaloproteinasade matriz que tienen la fórmula generalizada: en la cual R1 representa un sustituyente independientemente seleccionado entre el grupo que consiste en alquilo C6 -C12 ; alcoxi C5 -C12 ; alquiltio C5 -C12 ; poliéter de la fórmula R2 O(C2 H4 O)a -; donde a es 1 ó 2; y R2 es alquilo C1 -C5 ; fenilo o bencilo; y alquinilo sustituido de la fórmula R3 (CH2 )b -C=C- en la cual el b es 1-10 y R3 es H-, HO- o R4 O- donde R4 es alquilo C1 -C3 ; fenilo, o bencilo; Las porciones alquilo, fenilo y bencilo de R1 pueden contener por lo menos un sustituyente farmacéuticamente aceptable seleccionado entre halógeno, alquilo de bajo peso molecular, haloalquilo, -VN, -NO2 , -CO2 R6 , -OCOR6 , CH2 OR6 , -CONR6 R7 , -COR6 Y -OR8 en donde R6 representa H o alquilo de bajo peso molecular; H o alquilo de bajo peso molecular; R6 y R7 juntos con el nitrógeno al cual están unidos forman un anillo morfolina; y R8 representa H, alquilo de bajo peso molecular o haloalquilo; el subíndice n es 2-4; R5 representa un sustituyente independientemente seleccionado entre el grupo que consiste en fenilo; imidoilo de 4-12 átomos de carbono; (3H)-benzo-1,2,3-triazin-4-on-3-ilo; N-sacarinilo; (2H)-ftalazin-1-on-2-ilo; 2-benzoxazolin-2-on-3-ilo; 5,5-dimetiloxazolidin-2,4-dion-3-ilo; y tiazolidin-2,4-dion-3-ilo; las porciones fenilo y benzo de R5 pueden contener por lo menos un sustituyente farmacéuticamente aceptable seleccionado entre halógeno, alquilo de bajo peso molecular, haloalquilo, -CN, -NO2 , -CO2 R6 , -OCOR6 , CH2 OR6 , -CONR6 R7 , COR6 , Y -OR8 , en donde R6 representa H o alquilo de bajo peso molecular; R7 representa H o alquilo de bajo peso molecular; o R6 y R7 juntos con el nitrógeno al cual están unidos forman un anillo morfolina; y R8 representa H, alquilo de bajo peso molecular o haloalquilo; y las sales farmacéuticamente aceptables de los mismos.

Organic electroluminescent element

本发明的目的在于作为高效率、高耐久性的有机EL元件用的材料提供空穴的注入·传输性能优异、具有电子阻挡能力、薄膜状态下的稳定性高、具有发光效率高的优异的特性的有机化合物，进而使用该化合物提供高效率、高耐久性的有机EL元件。有机EL元件，其特征在于，在阳极与阴极之间从阳极侧起依次至少包括第一空穴传输层、第二空穴传输层、绿色发光层和电子传输层，在所述第二空穴传输层、或者所述第一空穴传输层与所述电子传输层之间所配置的层叠膜中的至少一层中，含有由下述通式(1)表示的芳基胺化合物。 (式中，Ar 1 、Ar 2 、Ar 3 、Ar 4 可彼此相同也可不同，表示取代或未取代的芳香族烃基、取代或未取代的芳香族杂环基或者取代或未取代的稠合多环芳香族基团。L 1 表示取代或未取代的芳香族烃的2价基团、取代或未取代的芳香族杂环的2价基团、或者取代或未取代的稠合多环芳香族的2价基团。R 1 、R 2 、R 3 表示氢原子、重氢原子、氟原子、氯原子、氰基、硝基、可具有取代基的碳原子数1‑6的直链状或分支状的烷基、可具有取代基的碳原子数5‑10的环烷基、可具有取代基的碳原子数2‑6的直链状或分支状的烯基、可具有取代基的碳原子数1‑6的直链状或分支状的烷氧基、可具有取代基的碳原子数5‑10的环烷氧基、取代或未取代的芳香族烃基、取代或未取代的芳香族杂环基、取代或未取代的稠合多环芳香族基团、或者取代或未取代的芳氧基。n表示1～3的整数)。

Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and or modulate intracellular triacylglycerol and cholesterol stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and or increase insulin sensitivity ; and or modulate insulin secretion from pancreatic beta cells. More particularly said disorders are selected from the group consisting of insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperclycemia, dislipidemia, obesity, abnormalities of lipoprotein metabolism and any combinations. thereof.

Matrix metalloproteinase inhibitors

本发明涉及甲基磺酰胺和N-甲酰胺衍生物以及其合成方法。本发明还涉及含有这些衍生物的药物组合物和用所述化合物治疗以下疾病的方法：哮喘、风湿性关节炎、COPD、鼻炎、骨关节炎、银屑病性关节炎、银屑病、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化、齿龈炎、动脉粥样硬化、干眼、内膜增生（导致再狭窄和缺血性心力衰竭）、中风、肾脏疾病、肿瘤转移、和其他表征为过量表达和过度激活基质金属蛋白酶的炎性疾病。

? FUSION HETEROCYCLIC COMPOUNDS MODULATORS OF IONIC CHANNEL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE SODIUM CHANNEL LOCK ?.

La presente descripción se refiere a compuestos heterocíclicos fusionados que son inhibidores del canal de sodio, útiles en el tratamiento de diversos estados de enfermedad, incluyendo enfermedades cardiovasculares y diabetes. En realizaciones particulares, la estructura de los compuestos está dada por la Fórmula I:en donde Q, R1, X1, X2, Y y R2 son como se describen en la presente, a métodos para la preparación de los compuestos, y a composiciones farmacéuticas que los contienen.

MOLD CONTROL.

Fungicidal compounds of the formula (I) : <CHEM> and stereoisomers thereof, wherein R<1> is optionally substituted aryl or optionally substituted heteroaryl; Y is oxygen, sulphur or NR<4>; R<2>, R<3> and R<4>, which may be the same or different, are hydrogen, C1-4 alkyl or C2-4 alkenyl; X is halogen, C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, nitro or cyano; and n is 0 or an integer of 1 to 4; provided that when Y is oxygen, n is 0 and R<1> is unsubstituted phenyl at least one of R<2> and R<3> is other than hydrogen or methyl.

DERIVATIVES OF 3-ARIBUTIRICO ACID SUBSTITUTED AS INHIBITORS OF THE MATRIX METALOPROTEASE

SE PRESENTAN COMPUESTOS INHIBIDORES DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y UN PROCESO PARA USAR LOS MISMOS A FIN DE TRATAR UNA DIVERSIDAD DE TRASTORNOS FISIOLOGICOS. LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERALIZADA: DONDE R1 REPRESENTA ALQUILO C6-C12; ALCOXI C5-C12; ALQUILTIO C5-C12; UN POLIETER DE LA FORMULA R2O(C2H4O)A-; DONDE A ES 1 O 2; Y R2 ES ALQUILO C1-C5; FENILO O BENCILO; Y ALQUINILO SUSTITUIDO DE LA FORMULA R3(CH2)B-C=C-; EN LA CUAL EL B ES 1-10 Y R3 ES H-, HO- O R4O- DONDE R4 ES ALQUILO C1-C3, FENILO, O BENCILO. LAS PORCIONES ALQUILO, FENILO Y BENCILO DE R1 PUEDEN CONTENER POR LO MENOS UN SUSTITUYENTE FARMACEUTICAMENTE ACEPTABLE. EL SUBINDICE N ES 2-4. R5 REPRESENTA FENILO; IMIDOILO DE 4-12 ATOMOS DE CARBONO; (3H)-BENZO-1,2,3-TRIAZIN-4-ON-3-ILO; N-SACARINILO; (2H)-FTALAZIN-1-ON-2-ILO; 2-BENZOXAZOLIN-2-ON-3-ILO; 5,5-DIMETILOXAZOLIDIN-2,4-DION-3-ILO; Y TIAZOLIDIN-2,4-DION-3-ILO; LAS PORCIONES FENILO Y BENZO DE R5 PUEDEN CONTENER POR LO MENOS UN SUSTITUYENTE FARMACEUTICAMENTE ACEPTABLE. TAMBIEN ESTAN INCLUIDAS LAS SALES FARMACEUTICAMENTE ACEPTABLES DE ESTOS MATERIALES. PRESENTATION OF MATRIX METALOPROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS TO USE THEM TO TREAT A DIVERSITY OF PHYSIOLOGICAL DISORDERS. THE COMPOUNDS OF THE PRESENT INVENTION HAVE THE GENERALIZED FORMULA: WHERE R1 REPRESENTS ALKYL C6-C12; ALCOXI C5-C12; ALKYLTIO C5-C12; A POLYETER OF THE FORMULA R2O (C2H4O) A-; WHERE A IS 1 OR 2; AND R2 IS C1-C5 ALKYL; PHENYL OR BENCILUM; AND SUBSTITUTED ALKINYL FROM FORMULA R3 (CH2) B-C = C-; IN WHICH B IS 1-10 AND R3 IS H-, HO- OR R4O- WHERE R4 IS ALKYL C1-C3, PHENYL, OR BENCILUM. THE ALKYL, PHENYL AND BENCIL R1 PORTIONS MAY CONTAIN AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE SUBSTITUTE. SUB-INDEX N IS 2-4. R5 REPRESENTS PHENYL; IMIDOIL OF 4-12 CARBON ATOMS; (3H) -BENZO-1,2,3-TRIAZIN-4-ON-3-ILO; N-SACCHARINYL; (2H) -FTALAZIN-1-ON-2-ILO; 2-BENZOXAZOLIN-2-ON-3-ILO; 5,5 ...

Ruthenium-catalyzed cycloaddition of alkynes and organic azides

유기 아지드 및 알킨으로부터 1,5-이치환된 1,2,3-트리아졸 및 1,4,5-삼치환된 1,2,3-트리아졸을 레지오특이적으로 합성하기 위한 편리한 방법은 촉매적 루테늄을 사용한다. 유기 아지드, 알킨, 루테늄 촉매, 1,5-이치환된 1,2,3-트리아졸, 1,4,5-삼치환된 1,2,3-트리아졸. A convenient method for the regiospecific synthesis of 1,5-disubstituted 1,2,3-triazoles and 1,4,5-trisubstituted 1,2,3-triazoles from organic azides and alkyne is a catalyst. Use red ruthenium. Organic azide, alkyne, ruthenium catalyst, 1,5-disubstituted 1,2,3-triazole, 1,4,5-trisubstituted 1,2,3-triazole.

Compounds for the treatment of metabolic diseases

There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

(4,4-Difluorobut-3-enylthio) -substituted heterocyclic or carbocyclic ring compounds having pesticidal activity

5-phenyl-pentanoic acid derivatives as metrix metalloproteinase inhibitors for the treatment of asthma and other diseases

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases 5--

Fungicides

Fungicidal compounds of the formula (I) : <CHEM> and stereoisomers thereof, wherein R<1> is optionally substituted aryl or optionally substituted heteroaryl; Y is oxygen, sulphur or NR<4>; R<2>, R<3> and R<4>, which may be the same or different, are hydrogen, C1-4 alkyl or C2-4 alkenyl; X is halogen, C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, nitro or cyano; and n is 0 or an integer of 1 to 4; provided that when Y is oxygen, n is 0 and R<1> is unsubstituted phenyl at least one of R<2> and R<3> is other than hydrogen or methyl.

(4,4-difluorobut-3-enylthio)-substituted heterocyclic or carbocyclic ring compounds having pesticidal activity

본 발명은 하기 일반식 (I)의 화합물, 또는 이들의 염에 관한다; The present invention relates to compounds of the following general formula (I), or salts thereof; [화학식 I] [Formula I] R-S(O) n CH 2 CH 2 CH=CF 2 RS (O) n CH 2 CH 2 CH = CF 2 [식중, n은 0, 1 또는 2이고; R은 하기 화학식(II) 내지 화학식(XXI)의 그룹이며; [Wherein n is 0, 1 or 2; R is a group of formulas (II) to (XXI); S(O) n CH 2 CH 2 CH=CF 2 는 하나 이상의 R 1 (탄소 원자에 결합될 경우), R 2 , R 3 , R 4 , R 5 또는 R 6 이며; R 1 (탄소 원자에 결합될 경우), R 2 , R 3 , R 4 , R 5 및 R 6 는 각각 독립적으로 수소, 임의 치환된 알킬, 임의 치환된 알케닐, 알키닐, 싸이클로알킬, 알킬싸이클로알킬, 알콕시, 알케닐옥시, 알키닐옥시, 하이드록시알킬, 알콕시알킬, 임의 치환된 아릴, 임의 치환된 아릴알킬, 임의 치환된 헤테로아릴, 임의 치환된 헤테로아릴알킬, 임의 치환된 아릴 옥시, 임의 치환된 아릴알콕시, 임의 치환된 아릴옥시알킬, 임의 치환된 헤테로아릴옥시, 임의 치환된 헤테로아릴알콕시, 임의 치환된 헤테로아릴옥시알킬, 할로알킬, 할로알케닐, 할로알키닐, 할로알콕시, 할로알케닐옥시, 할로알키닐옥시, 할로겐, 하이드록시, 시아노, 니트로, -NR 7 R 8 , -NR 7 COR 8 , -NR 7 CSR 8 , -NR 7 SO 2 R 8 , -N(SO 2 R 7 )(SO 2 R 8 ), -COR 7 , -CONR 7 R 8 , -알킬CONR 7 R 8 , -CR 7 NR 8 , -COOR 7 , -OCOR 7 , -SR 7 , -SOR 7 , -SO 2 R 7 , -알킬SR 7 , -알킬SOR 7 , -알킬SO 2 R 7 , -OSO 2 R 7 , -SO 2 NR 7 R 8 , -CSNR 7 R 8 , -SiR 7 R 8 R 9 , -OCH 2 CO 2 R 7 , -OCH 2 CH 2 CO 2 R 7 , -CONR 7 SO 2 R 8 , -알킬CONR 7 SO 2 R 8 , -NHCONR 7 R 8 , -NHCSNR 7 R 8 , 이거나 또는 인접쌍 R 1 , R 2 , R 3 , R 4 , R 5 및 R 6 가 함께 융합하여 5- 또는 6- 원 탄소환식 또는 복소환식 고리를 형성하고; R 1 (질소 원자에 결합될 경우)은 수소, 임의 치환된 알킬, 싸이클로 알킬, 알킬싸이클로알킬, 하이드록시알킬, 알콕시알킬, 임의 치환된 아릴, 임의 치환된 아릴알킬, 임의 치환된 아릴옥시알킬, 임의 치환된 헤테로아릴, 임의 치환된 헤테로아릴알킬, 임의 치환된 헤테로아릴옥시알킬, 할로알킬, 하이드록시, 시아노, 니트로, -NR 7 R 8 , -NR 7 COR 8 , -NR 7 CSR 8 , -NR 7 COOR 8 , -NR 7 SO 2 R 8 , -N(SO 2 R 7 )(SO 2 R 8 ), -COR 7 , -CONR 7 R 8 , -알킬CONR 7 R 8 , -CR 7 NR 8 , -COOR 7 , -OCOR 7 , -SOR 7 , -SO 2 R 7 , -알킬SR 7 , -알킬SOR 7 , -알킬SO 2 R 7 , -OSO 2 R 7 , -SO 2 NR 7 NR 8 , -SR 7 , -SOR 7 , -SO 2 R 7 , -CSNR 7 R 8 , -SiR 7 R 8 R 7 , -OCH 2 CO 2 R 7 , -OCH 2 CH 2 CO 2 R 7 , -CONR 7 RSO 2 R 8 , -알킬CONR 7 SO 2 R 8 , -NHCOR 7 R 8 또는 -NHCSR 7 R 8 이고 ; R 7 , R 8 및 R 9 는 각각 독립적으로 수소, 임의 치환된 알킬, 임의 치환된 알케닐, 알키닐, 임의 치환된 아릴, 또는 임의 치환된 아릴알킬, 할로알킬, 할로알케닐, 할로알키닐, 할로 또는 하이드록시임. S (O ...

Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

Sulfenamides, process for their preparation, their utilisation as medicines and their preparation.

Novel sulphenamides of the general formula I < IMAGE > in which R<1>, R<2> and R<3> are as defined in the description, a process for their preparation, their utilisation as medicines, in particular their utilisation as lipoxygenase inhibitors, medicaments containing them and the preparation thereof.

Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and or modulate intracellular triacylglycerol and cholesterol stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and or increase insulin sensitivity ; and or modulate insulin secretion from pancreatic beta cells. More particularly said disorders are selected from the group consisting of insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperclycemia, dislipidemia, obesity, abnormalities of lipoprotein metabolism and any combinations. thereof.

Compounds for the treatment of metabolic diseases

提供了能够调节G蛋白偶联受体GPR40的新化合物、包含该化合物的组合物和它们用于控制体内胰岛素水平和治疗例如II型糖尿病、高血压、酮酸中毒、肥胖症、葡萄糖耐受不良和高胆固醇血症的病况和与不正常的高或低血浆脂蛋白、甘油三酯或葡萄糖水平相关的障碍的方法。

Ruthenium-catalyzed cycloaddition of alkynes and organic azides

A convenient process for the regioselective synthesis of 1 ,5-disubstituted 1 ,2,3-triazoles and 1 ,4,5-trisubstituted 1 ,2,3-triazoles from organic azides and alkynes employs catalytic ruthenium.

5-FENYL-PENTANOIC ACID DERIVATIVE AS FUNDAMENTAL METAL PROTEIN Suspensions for the Treatment of Asthma and Other Diseases

Η παρούσα εφεύρεση αναφέρεται σε Ενώσεις που έχουν την δομή του Τύπου Ι: όπου το n είναι ένας ακέραιος από 1 έως 5· το R1 είναι προαιρετικά υποκατεστημένο αλκύλιο, αλκενύλιο, αλκινύλιο, κυκλοαλκύλιο, αρύλιο, ετεροκυκλύλιο, ετεροαρύλιο, αραλκύλιο, αλκοξυ, αρυλοξυ, αλκενυλοξυ ή αλκινυλοξυ· το R2 είναι προαιρετικά υποκατεστημένο αλκενύλιο, αλκινύλιο, αρύλιο, ετεροκυκλύλιο, ετεροαρύλιο, κυκλοαλκύλιο, ΝR4R5, -ΝΗC(=Υ)R4, -ΝΗC(=Υ)ΝR5RΧ, -ΝΗC(=Ο)ΟR4, -ΝΗSΟ2R4, C(=Υ)ΝR4R5, C(=Ο)ΟR6 [όπου το Υ είναι οξυγόνο ή θείο], ΟR5, -ΟC(=Ο)ΝR4R5, Ο-ακύλιο, S(O)mR4, -SΟ2Ν(R4)2, κυανό, αμιδινο ή γουανιδινο [όπου το R4 είναι αλκύλιο, αλκενύλιο, αλκινύλιο, κυκλοαλκύλιο, αρύλιο, ετεροκυκλύλιο, ετεροαρύλιο, αραλκύλιο, ετεροαρυλαλκύλιο, ετεροκυκλυλαλκύλιο ή κυκλοαλκυλαλκύλιο και το m είναι ένας ακέραιος 0-2· το R5 είναι υδρογόνο ή R4· το RX είναι R4 ή -SΟ2Ν(R4)2 και το R6 είναι υδρογόνο, αλκύλιο, κυκλοαλκύλιο, αραλκύλιο, ετεροαρυλαλκύλιο, ετεροκυκλυλαλκύλιο ή κυκλοαλκυλαλκύλιο]· το R3 είναι υδρογόνο, φθόριο, αλκύλιο, κυκλοαλκυλαλκύλιο ή αραλκύλιο· το Α είναι ΟΗ, ΟR4, -ΟC(=Ο)ΝR4R5, Ο-ακύλιο, ΝΗ2, ΝR4R5, -ΝΗC(=Υ)R4, -ΝΗC(=Υ)ΝR5RX, -ΝΗC(=Ο)ΟR4, -ΝΗSΟ2R4, και σε μεθόδους σύνθεσης των ιδίων. Η εφεύρεση αυτή σχετίζεται επίσης με φαρμακολογικές συνθέσεις που περιέχουν τις ενώσεις της παρούσας εφεύρεσης, και μεθόδους αγωγής άσθματος, ρευματοειδούς αρθρίτιδας, χρόνιας αποφρακτικής πνευμονοπάθειας (CΟΡD), ρινίτιδας, οστεοαρθρίτιδας, ψωριασικής αρθρίτιδας, ψωρίασης, πνευμονικής ίνωσης, πνευμονικής φλεγμονής, συνδρόμου οξείας αναπνευστικής δυσχέρειας, περιοδοντίτιδας, σκλήρυνσης κατά πλάκας, ουλίτιδας, αρτηριοσκλήρυνσης, ενδοθηλιακής υπερπλασίας, που οδηγεί σε επαναστένωση και ισχαιμική καρδιακή ανεπάρκεια, αποπληξίας, νεφρικών νόσων, νεοπλασματικής μετάστασης, και άλλων φλεγμονωδών διαταραχών χαρακτηριζομένων από

New phenylalanine derivatives

本発明は、α４インテグリン阻害作用を有する下記のフェニルアラニン誘導体またはその類縁体、及びα４インテグリンに関与する各種疾病の治療薬に関する。 The present invention relates to the following phenylalanine derivatives having analog α4 integrin inhibitory activity or analogs thereof, and therapeutic agents for various diseases related to α4 integrin.

Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren

Organic compound and organic light-emitting element

An organic compound represented by formula [1]. The compounds are of the class of diacenaphthochrysene compound, useful as organic light emitting device.In the formula [1], R1 to R18 are each independently selected from the group consisting of a hydrogen atom and a substituent.

Neues phenylalaninderivat

Substituierte benzoylketone, verfahren zu ihrer herstellung und ihre verwendung als herbizide

(4,4-difluorbut-3-enylthio)-substituierte heterocyckische oder carbocyclische ring- verbindungen mit pesticider wirkung

Lisofyllin-analogika und ihre pharmazeutischen verwendungen

荧蒽衍生物、发光元件以及光电转换元件

本发明提供一种荧蒽衍生物，含有其的光电转换元件及发光元件。本发明的荧蒽衍生物具有包含荧蒽主体和氮杂苯系主体的特定结构。根据本发明可提供同时实现高发光效率、低驱动电压、以及长耐久寿命的有机薄膜发光元件。

Hemmung von matrixmetalloproteasen durch 2- substituierte-4-(4-substituiertphenyl)-4- oxobutansäuren

Compounds for use in the treatment of liver disease

Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.

5-phenyl-pentansäurederivate als matrixmetalloproteinase-inhibitoren zur behandlung von asthma und anderen erkrankungen

新型的发光元件用化合物以及包含所述发光元件用化合物的有机发光元件

本发明提供一种以下述化学式1表示的发光元件用化合物以及包含所述发光元件用化合物的有机发光元件。<化学式1>

신규한 발광 소자용 화합물 및 이를 포함하는 유기 발광 소자

본 발명은 하기 화학식 1로 표시되는 발광 소자용 화합물 및 이를 함유하는 유기 발광 소자를 제공한다. <화학식1>

Compunds

一种具有杀线虫活性的含氮杂环化合物及其制法和用途

本发明涉及一种具有杀线虫活性的含氮杂环化合物及其制法和用途。具体地，本发明公开了具有式(I)化合物或其光学异构体、顺反异构体或农药学上可接受的盐，及其制备方法。本发明还公开了包含上述化合物的农用组合物及其用途。上述化合物具有优异的杀线虫活性。

Novel compound for capping layer, and organic light-emitting device comprising same

A novel compound for a capping layer, and an organic light-emitting device containing the same are proposed.

丙二烯合茀衍生物、發光元件以及光電轉換元件

本發明提供一種丙二烯合茀衍生物，含有其的光電轉換元件及發光元件。本發明的丙二烯合茀衍生物具有包含丙二烯合茀主體和氮雜苯系主體的特定結構。根據本發明可提供同時實現高發光效率、低驅動電壓、以及長耐久壽命的有機薄膜發光元件。

신규한 캡핑층용 화합물 및 이를 포함하는 유기 발광 소자

본 발명은 하기 화학식 1로 표시되는 캡핑층용 화합물 및 이를 함유하는 유기 발광 소자를 제공한다. <화학식1>

Fluorine-containing compound

新規なキャッピング層用化合物およびそれを含む有機発光素子

本発明は、新規なキャッピング層用化合物及びそれを含有する有機発光素子を提供する。

Compound for capping layer and organic light emitting device including same

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

A novel pyrazole PPAR modulator

Derivados de pirazol como moduladores de ppar

SE REFIERE AL COMPUESTO ACIDO {2-METIL-4-[3-METIL-1-(4-TRIFLUOROMETILFENIL)-1H-PIRAZOL-4-ILMETILSULFANIL]-FENOXI}ACETICO Y A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. ESTE COMPUESTO ES UN MODULADOR SELECTIVO DE UN RECEPTOR ACTIVADO DE PROLIFERADOR DE PEROXISOMA, ESPECIFICAMENTE EL RECEPTOR PPAR DELTA Y/O PPAR ALFA Y ES UTIL EN EL TRATAMIENTO Y LA PREVENCION DE SINDROME METABOLICO, DIABETES TIPO II, HIPERGLICEMIA, HIPERLIPIDEMIA, OBESIDAD, COAGULOPATIA, HIPERTENSION, ATEROSCLEROSIS Y/O TRANSTORNOS RELACIONADOS CON EL SINDROME METABOLICO Y ENFERMEDADES CARDIOVASCULARES, ADEMAS PUEDEN SER UTILES PARA REDUCIR LOS NIVELES DE FIBRINOGENO, AUMENTAR HDL, TRATAR ENFERMEDAD RENAL CONTROLAR EL PESO DESEABLE, TRATAR ENFERMEDADES DESMIELINIZANTES Y ENFERMEDADES INFLAMATORIAS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION DEL COMPUESTO

Acido {2-metil-4-[3-metil-1-(4-trifluorometilfenil)-1h-pirazol-4-ilmetil-sulfanil]fenoxi}acetico, moduladores del receptor activado de proliferador de peroxisoma ppar, composicion farmaceutica, utiles para tratar diabetes mellitus, aterosclerosis, ar

ACIDO (2-METIL-4-(3-METIL-1-(4-TRIFLUOROMETILFENIL)-1H-PIRAZOL-4-ILMETIL-SULFANIL)FENOXI)ACETICO DE FORMULA I Y SUS SALES, SOLVATOS E HIDRATOS FARMACEUTICAMENTE ACEPTABLES DEL MISMO, MODULADORES DEL RECEPTOR ACTIVADO DE PROLIFERADOR DE PEROXISOMA PPAR; COMPOSICION FARMACEUTICA QUE LOS CONTIENEN; Y SU USO EN LA PREPARACION DE UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE DIABETES MELLITUS, ATEROSCLEROSIS, ARTRITIS, ENFERMEDAD DEMIELINIZANTE Y ENFERMEDADES INFLAMATORIAS.

과불소폴리에테르-벤조페논 화합물, 이를 포함하는 반사방지 코팅 첨가제 및 코팅 조성물

본 발명은 과불소폴리에테르(PFPE)에 벤조페논(BP) 화합물이 결합된 과불소폴리에테르-벤조페논 화합물, 이를 포함하는 반사방지 코팅 첨가제 및 코팅 조성물을 제공한다. 본 발명의 과불소폴리에테르-벤조페논 화합물, 이를 포함하는 반사방지 코팅 첨가제 및 코팅 조성물은 표면 코팅 기술 분야에서 광대역 반사 방지, 오염 방지 거동, 우수한 내마모성, 열 변화와 상대 습도에 대한 높은 내구성을 갖춘 효율적인 코팅용 물질로서 유용하게 사용될 수 있다.

荧蒽衍生物、发光元件以及光电转换元件

本发明提供一种荧蒽衍生物，含有其的光电转换元件及发光元件。本发明的荧蒽衍生物具有包含荧蒽主体和氮杂苯系主体的特定结构。根据本发明可提供同时实现高发光效率、低驱动电压、以及长耐久寿命的有机薄膜发光元件。

酮腈类化合物及其制备方法与应用

本发明公开了一种酮腈类化合物及其制备方法与应用。具体地，本发明涉及一种如式I或式I’所示的化合物、含其的组合物、及其用途。本发明的化合物具有优异的杀菌、杀螨和杀虫活性。

新型的发光元件用化合物以及包含所述发光元件用化合物的有机发光元件

本发明提供一种以下述化学式1表示的发光元件用化合物以及包含所述发光元件用化合物的有机发光元件。<化学式1>